ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0540

Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A Post-hoc Analysis of Four Phase III Clinical Trials of SLE

Sandra Jägerback1, Alvaro Gomez1 and Ioannis Parodis2, 1Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden

Meeting: ACR Convergence 2022

Keywords: Biomarkers, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Abstracts: SLE – Diagnosis, Manifestations, and Outcomes I: Renal Aspects

Session Type: Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: In patients with systemic lupus erythematosus (SLE), renal involvement is associated with high morbidity, and renal flare is a major contributing factor to poor long-term prognosis. Lupus nephritis (LN) still leads to end-stage kidney disease in approximately 10–20 % of SLE patients. Identification of patients with susceptibility to develop a renal flare despite immunosuppressant therapy is needed toward individualised treatment optimisation, which was the scope of the present investigation.

Methods: In this study, we used pooled data from four phase III randomised controlled trials of belimumab in patients with SLE, i.e. BLISS-52 (NCT01597622; N=865), BLISS-76 (NCT00410384; N=819), BLISS Northeast Asia (NCT1597622; N=677), and BLISS-SC (NCT01484496; N=836). SLE patients with moderate to severe disease activity were recruited while active severe LN was an exclusion criterion. Participants were on non-biologic standard therapy, and were assigned to IV belimumab (1 mg/kg or 10 mg/kg every fourth week), SC belimumab 200 mg weekly, or placebo. The outcome of this investigation was development of renal flares, defined as a reproducible (i) increase in proteinuria to >1 g/day if the baseline value was < 0.2 g/d, >2 g/day if the baseline value was 0.2–1.0 g/d, or >2 times the baseline value if the baseline value was >1g/d, (ii) increase in serum creatinine ≥20% or 0.3 mg/dL, accompanied by proteinuria, haematuria or red blood cell (RBC) casts, or (iii) new haematuria of glomerular origin, accompanied by proteinuria or RBC casts. Cox proportional hazards regression models were employed. We next adjusted the models for age, sex, ethnicity, BMI, organ damage, baseline SLE disease activity, previous renal involvement, baseline prednisone equivalent dose, and use of immunosuppressants and belimumab.

Results: The mean age of the patients was 36.7 years, 94% were women, and 192 developed a renal flare after a median of 141 days. The proportion of patients with a history of renal involvement was 54.6%. In univariable Cox regression analysis, low C3 levels at baseline were associated with an increased risk to develop a renal flare (hazard ratio, HR: 2.6; 95% confidence interval, CI: 1.9–3.5; p< 0.001; figure), as did anti-dsDNA positivity (HR: 1.8; 95% CI: 1.3–2.6; p=0.001), anti-Sm positivity (HR: 1.6; 95% CI: 1.1–2.5; p=0.022), plasma albumin levels (HR: 0.9; 95% CI: 0.8–0.9; p< 0.001), and proteinuria (HR: 1.5; 95% CI: 1.4–1.6; p< 0.001). Low C4 levels were not associated with renal flare development. In adjusted analysis, the association with low C3 levels, plasma albumin and proteinuria remained significant.

Conclusion: Low C3, plasma albumin and proteinuria levels at baseline were associated with renal flare development in a clinical trial setting encompassing patients with active SLE yet no severe active LN, as were anti-dsDNA and anti-Sm positivity yet only in unadjusted models. While C3 and anti-dsDNA are markers of known importance for surveillance of renal SLE, anti-Sm and plasma albumin are not established markers of renal flare; investigation of potential complemental predictive properties across these traditional biomarkers has merit.

Supporting image 1


Disclosures: S. Jägerback, AstraZeneca; A. Gomez, None; I. Parodis, GlaxoSmithKlein(GSK), Amgen, AstraZeneca, Aurinia Pharmaceuticals, Eli Lilly, Gilead, Janssen, Novartis, Roche.

To cite this abstract in AMA style:

Jägerback S, Gomez A, Parodis I. Evaluation of Traditional Laboratory Markers as Predictors of Renal Flares: A Post-hoc Analysis of Four Phase III Clinical Trials of SLE [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-traditional-laboratory-markers-as-predictors-of-renal-flares-a-post-hoc-analysis-of-four-phase-iii-clinical-trials-of-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-traditional-laboratory-markers-as-predictors-of-renal-flares-a-post-hoc-analysis-of-four-phase-iii-clinical-trials-of-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology